Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Nebulized Ensifentrine Suspension; 3 mg Phase 2 Results Expected
Nebulized Ensifentrine Suspension; 3 mg • Non-cystic Fibrosis Bronchiectasis
Target Indication
Non-cystic Fibrosis Bronchiectasis
Clinical Trial
NCT06559150Last updated: 12/13/2025
Chronic Obstructive Pulmonary Disease
COPD
COPD
COPD
Pulmonary Disease, Chronic Obstructive